My PhD-thesis (immune-activating components of bacteria; Prof. Dr. Dr. Thomas Hartung) introduced me to preparation /purification and bioassays, which until today influences my work on immune-activating / pyrogenic substances. I started at the PEI 2001 with the development and validation of the Monocyte activation test (MAT).
My current duties as deputy at the PEI are drug QC by LAL (all methods including rFC) and Pyrogen testing (former rabbit pyrogen test, now replaced by MAT) and scientifically the exploration of the MAT. Our actual interests are drugs with intrinsic pyrogenicity, Non-Endotoxin Pyrogens, Outer membrane vesicles, synergistic effects, low Endotoxin recovery (LER) and iPSC-derived macrophages for QC including MAT.
Additionally I am the Chair of the EDQM Working Party “Bacterial Endotoxin Test”.
With an ever-increasing focus on sustainability across the pharmaceutical industry, many companies are looking to recombinant methods for bacterial endotoxin testing. During this panel discussion, experts will discuss the latest guidelines and regional variations on recombinant Factor C (rFC) and recombinant Cascade Reagents (rCR). Make sure you join to:
SME Testing Services
Lonza
Chief Microbiologist, Global Quality
AstraZeneca
Deputy Head Microbiology Safety Section
Paul-Ehrlich-Institut
Senior Principal Scientist
Merck Research Laboratories
Head of QA GxP Compliance and Sterility Assurance
Bio Products Laboratory
© Copyright 2024 Russell Publishing Limited.
All Rights Reserved.
Registered address: Court Lodge, Hogtrough Hill, Brasted, Kent, TN16 1NU, United Kingdom
Company registration number: 2709148
+44 (0)1959 563 311
[email protected]
Access the latest news, articles, interviews and insights at European Pharmaceutical Review
